The DOI matches its Crossref record; 52 of the 54 references it cites were found in a registry or an index.
GLP-1 Receptor Agonist Treatment Increases Bone Formation and Prevents Bone Loss in Weight-Reduced Obese Women
Abstract
CONTEXT: Recent studies indicate that glucagon-like peptide (GLP)-1 regulates bone turnover, but the effects of GLP-1 receptor agonists (GLP-1 RAs) on bone in obese weight-reduced individuals are unknown. OBJECTIVE: To investigate the role of GLP-1 RAs on bone formation and weight loss-induced bone mass reduction. DESIGN: Randomized control study. SETTING: Outpatient research hospital clinic. PARTICIPANTS: Thirty-seven healthy obese women with body mass index of 34 ± 0.5 kg/m(2) and age 46 ± 2 years. INTERVENTION: After a low-calorie-diet-induced 12% weight loss, participants were randomized to treatment with or without administration of the GLP-1 RA liraglutide (1.2 mg/d) for 52 weeks. In case of weight gain, up to two meals per day could be replaced with a low-calorie-diet product to maintain the weight loss. MAIN OUTCOME MEASURES: Total, pelvic, and arm-leg bone mineral content (BMC) and bone markers [C-terminal telopeptide of type 1 collagen (CTX-1) and N-terminal propeptide of type 1 procollagen (P1NP)] were investigated before and after weight loss and after 52-week weight maintenance. Primary endpoints were changes in BMC and bone markers after 52-week weight maintenance with or without GLP-1 RA treatment. RESULTS: Total, pelvic, and arm-leg BMC decreased during weight maintenance in the control group (P < .0001), but not significantly in the liraglutide group. Thus, total and arm-leg BMC loss was four times greater in the control group compared to the liraglutide group (estimated difference, 27 g; 95% confidence interval, 5-48; P = .01), although the 12% weight loss was maintained in both groups. In the liraglutide group, the bone formation marker P1NP increased by 16% (7 ± 3 μg/L) vs a 2% (-1 ± 4 μg/L) decrease in the control group (P < .05). The bone resorption marker CTX-1 collagen did not change during the weight loss maintenance phase. CONCLUSIONS: Treatment with a long-acting GLP-1 RA increased bone formation by 16% and prevented bone loss after weight loss obtained through a low-calorie diet, supporting its role as a safe weight-lowering agent.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In euglycemic individuals, liraglutide increased procollagen type I N-terminal propeptide (P-PINP) levels by 16%, compared with a 2% decrease in the placebo group [42].”
From Nutrition and Physical Activity in Optimizing Weight Loss and Lean Mass Preservation in the Incretin-Based Medications Era: A Narrative Review (2025) · cites this paper as [42]
In the citing paper
“Treatment with liraglutide has been shown to increase bone formation in body weight-reduced obese women when compared to placebo (14).”
In the citing paper
“The reduction in PINP in the exenatide-treated group contrasts a previously reported increase of PINP in obese women, who experienced a 12% body weight reduction after 12 months of liraglutide treatment (14).”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371
Self-citationBone “mass” and the “mechanostat”: A proposal
Frost, H. M. (1987) · The Anatomical Record · doi:10.1002/ar.1092190104 · Cited by 2,132
Systematic Review of Type 1 and Type 2 Diabetes Mellitus and Risk of Fracture
Janghorbani, M., van Dam, R. M., Willett, W. C., & Hu, F. B. (2007) · American Journal of Epidemiology · doi:10.1093/aje/kwm106 · Cited by 1,223
for the IOF-IFCC Bone Marker Standards Working Group, Vasikaran, S., Eastell, R., Bruyère, O., Foldes, A. J., Garnero, P., Griesmacher, A., McClung, M., Morris, H. A., Silverman, S., et al. (2011) · Osteoporosis International · doi:10.1007/s00198-010-1501-1 · Cited by 1,212
Astrup, A., Rössner, S., Van Gaal, L., Rissanen, A., Niskanen, L., Al Hakim, M., Madsen, J., Rasmussen, M. F., & Lean, M. E. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61375-1 · Cited by 1,163
Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis
Loke, Y. K., Singh, S., & Furberg, C. D. (2008) · Canadian Medical Association Journal · doi:10.1503/cmaj.080486 · Cited by 553
Mechanical and textural properties of pelvic trabecular bone
Dalstra, M., Huiskes, R., Odgaard, A., & van Erning, L. (1993) · Journal of Biomechanics · doi:10.1016/0021-9290(93)90014-6 · Cited by 361
Bone Metabolism in Obesity and Weight Loss
Shapses, S. A., & Sukumar, D. (2012) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.012809.104655 · Cited by 358
Role of Gastrointestinal Hormones in Postprandial Reduction of Bone Resorption
Henriksen, D. B., Alexandersen, P., Bjarnason, N. H., Vilsbøll, T., Hartmann, B., Henriksen, E. E., Byrjalsen, I., Krarup, T., Holst, J. J., & Christiansen, C. (2003) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2003.18.12.2180 · Cited by 331
Self-citationFærch, K., Torekov, S. S., Vistisen, D., Johansen, N. B., Witte, D. R., Jonsson, A., Pedersen, O., Hansen, T., Lauritzen, T., Sandbæk, A., et al. (2015) · Diabetes · doi:10.2337/db14-1751 · Cited by 321
Self-citationThe Murine Glucagon-Like Peptide-1 Receptor Is Essential for Control of Bone Resorption
Yamada, C., Yamada, Y., Tsukiyama, K., Yamada, K., Udagawa, N., Takahashi, N., Tanaka, K., Drucker, D. J., Seino, Y., & Inagaki, N. (2008) · Endocrinology · doi:10.1210/en.2007-1292 · Cited by 318
Glucagon-like peptide 1(GLP-1) in biology and pathology
Meier, J. J., & Nauck, M. A. (2005) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.538 · Cited by 288
Vestergaard, P., Rejnmark, L., & Mosekilde, L. (2008) · Calcified Tissue International · doi:10.1007/s00223-008-9195-5 · Cited by 282
Osteoblast-Derived Cells Express Functional Glucose-Dependent Insulinotropic Peptide Receptors1
Bollag, R. J., Zhong, Q. P. W., Phillips, P., Min, L., Zhong, L., Cameron, R. S., Mulloy, A. L., Rasmussen, H., Qin, F., Ding, K., et al. (2000) · Endocrinology · doi:10.1210/endo.141.3.7366 · Cited by 265
Bone, Body Weight, and Weight Reduction: What Are the Concerns?
Shapses, S. A., & Riedt, C. S. (2006) · The Journal of Nutrition · doi:10.1093/jn/136.6.1453 · Cited by 247
Bone turnover markers in the management of postmenopausal osteoporosis
Brown, J. P., Albert, C., Nassar, B. A., Adachi, J. D., Cole, D., Davison, K. S., Dooley, K. C., Don-Wauchope, A., Douville, P., Hanley, D. A., et al. (2009) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2009.04.001 · Cited by 204
Madsbad, S., Kielgast, U. L., Asmar, M., Deacon, C. F., Torekov, S. S., & Holst, J. J. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01357.x · Cited by 202
Self-citationJensen, L. B., Kollerup, G., QUAADE, F., & Sørensen, O. H. (2001) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2001.16.1.141 · Cited by 201
Multisystemic Functions of Alkaline Phosphatases
Buchet, R., Millán, J. L., & Magne, D. (2013) · Methods in molecular biology · doi:10.1007/978-1-62703-562-0_3 · Cited by 200
Ma, X., Meng, J., Jia, M., Bi, L., Zhou, Y., Wang, Y., Hu, J., He, G., & Luo, X. (2013) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1898 · Cited by 200
Costanzo, P., Cleland, J. G. F., Pellicori, P., Clark, A. L., Hepburn, D., Kilpatrick, E. S., Perrone-Filardi, P., Zhang, J., & Atkin, S. L. (2015) · Annals of Internal Medicine · doi:10.7326/m14-1551 · Cited by 199
Hegedüs, L., Moses, A. C., Zdravkovic, M., Le Thi, T., & Daniels, G. H. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2318 · Cited by 194
Effect of GLP-1 Treatment on Bone Turnover in Normal, Type 2 Diabetic, and Insulin-Resistant States
Nuche‐Berenguer, B., Moreno, P., Esbrit, P., Dapía, S., Caeiro, J. R., Cancelas, J., Haro‐Mora, J. J., & Villanueva‐Peñacarrillo, M. L. (2009) · Calcified Tissue International · doi:10.1007/s00223-009-9220-3 · Cited by 192
Nauck, M. A., Vilsbøll, T., Gallwitz, B., Garber, A. J., & Madsbad, S. (2009) · Diabetes Care · doi:10.2337/dc09-s315 · Cited by 182
Self-citationMabilleau, G., Mieczkowska, A., & Chappard, D. (2014) · Journal of Diabetes · doi:10.1111/1753-0407.12102 · Cited by 178
Overweight Postmenopausal Women Lose Bone With Moderate Weight Reduction and 1 g/day Calcium Intake
Riedt, C. S., Cifuentes, M., Stahl, T. J., Chowdhury, H. A., Schlussel, Y., & Shapses, S. A. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.041132 · Cited by 174
Four-month treatment with GLP-2 significantly increases hip BMD
Henriksen, D. B., Alexandersen, P., Hartmann, B., Adrian, C. L., Byrjalsen, I., Bone, H. G., Holst, J. J., & Christiansen, C. (2009) · Bone · doi:10.1016/j.bone.2009.07.008 · Cited by 164
Self-citationNuche‐Berenguer, B., Portal‐Núñez, S., Moreno, P., González, N., Acitores, A., López‐Herradón, A., Esbrit, P., Valverde, I., & Villanueva‐Peñacarrillo, M. L. (2010) · Journal of Cellular Physiology · doi:10.1002/jcp.22243 · Cited by 146
Exendin-4 exerts osteogenic actions in insulin-resistant and type 2 diabetic states
Nuche‐Berenguer, B., Moreno, P., Portal‐Núñez, S., Dapía, S., Esbrit, P., & Villanueva‐Peñacarrillo, M. L. (2009) · Regulatory Peptides · doi:10.1016/j.regpep.2009.06.010 · Cited by 144
Glucose-dependent insulinotropic peptide-overexpressing transgenic mice have increased bone mass
Xie, D., Zhong, Q., Ding, K.-H., Cheng, H., Williams, S., Correa, D., Bollag, W. B., Bollag, R. J., Insogna, K., Troiano, N., et al. (2007) · Bone · doi:10.1016/j.bone.2007.01.007 · Cited by 144
Rosiglitazone and pioglitazone increase fracture risk in women and men with type 2 diabetes
Aubert, R. E., Herrera, V., Chen, W., Haffner, S. M., & Pendergrass, M. L. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01225.x · Cited by 135
Riecke, B. F., Christensen, R., Christensen, P., Leeds, A., Boesen, M., Lohmander, S. L., Astrup, A. V., & Bliddal, H. (2010) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2010.02.012 · Cited by 127
Glucose-dependent insulinotropic polypeptide inhibits bone resorption in humans.
Nissen, A., Christensen, M., Knop, F., Vilsbøll, T., Holst, J., & Hartmann, B. (2014) · Journal of Clinical Endocrinology and Metabolism · doi:10.1210/jc.2014-2547 · Cited by 122
Self-citationIepsen, E. W., Lundgren, J., Dirksen, C., Jensen, J.-E., Pedersen, O., Hansen, T., Madsbad, S., Holst, J. J., & Torekov, S. S. (2015) · International Journal of Obesity · doi:10.1038/ijo.2014.177 · Cited by 118
Self-citationBunck, M. C. M., Eliasson, B., Cornér, A., Heine, R. J., Shaginian, R. M., Taskinen, M., Yki‐Järvinen, H., Smith, U., & Diamant, M. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01355.x · Cited by 112
Mabilleau, G., Mieczkowska, A., Irwin, N., Flatt, P. R., & Chappard, D. (2013) · Journal of Endocrinology · doi:10.1530/joe-13-0146 · Cited by 107
Effects of Body Size and Skeletal Site on the Estimated Prevalence of Osteoporosis in Women and Men
Melton, L. J., Khosla, S., Achenbach, S. J., O’Connor, M. K., O’Fallon, W. M., & Riggs, B. L. (2000) · Osteoporosis International · doi:10.1007/s001980070037 · Cited by 101
Bilezikian, J. P., Josse, R. G., Eastell, R., Lewiecki, E. M., Miller, C. G., Wooddell, M. J., Northcutt, A. R., Kravitz, B. G., Paul, G., Cobitz, A. R., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-4018 · Cited by 98
GLP ‐1 Receptor Agonists for Type 2 Diabetes Mellitus: Recent Developments and Emerging Agents
Trujillo, J. M., & Nuffer, W. A. (2014) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1507 · Cited by 97
Deng, H., Xu, F., Davies, K. M., Heaney, R. P., & Recker, R. R. (2002) · Journal of Bone and Mineral Metabolism · doi:10.1007/s007740200052 · Cited by 84
Osteoblast-Derived Cells Express Functional Glucose-Dependent Insulinotropic Peptide Receptors
Bollag, R. J. (2000) · Endocrinology · doi:10.1210/en.141.3.1228 · Cited by 63
Beyond Glycemic Control in Diabetes Mellitus: Effects of Incretin-Based Therapies on Bone Metabolism
Ceccarelli, E., Guarino, E., Merlotti, D., Patti, A., Gennari, L., Nuti, R., & Dotta, F. (2013) · Frontiers in Endocrinology · doi:10.3389/fendo.2013.00073 · Cited by 51
Mieczkowska, A., Bouvard, B., Chappard, D., & Mabilleau, G. (2015) · Bone · doi:10.1016/j.bone.2015.01.003 · Cited by 49
Beneficial effects of a N-terminally modified GIP agonist on tissue-level bone material properties
Mabilleau, G., Mieczkowska, A., Irwin, N., Simon, Y., Audran, M., Flatt, P. R., & Chappard, D. (2014) · Bone · doi:10.1016/j.bone.2014.02.013 · Cited by 47
Hinton, P. S., LeCheminant, J. D., SMITH, B. K., Rector, R. S., & Donnelly, J. E. (2009) · Journal of the American College of Nutrition · doi:10.1080/07315724.2009.10719788 · Cited by 40
Christensen, P., Bartels, E. M., Riecke, B. F., Bliddal, H., Leeds, A., Astrup, A. V., Winther, K., & Christensen, R. (2011) · European Journal of Clinical Nutrition · doi:10.1038/ejcn.2011.201 · Cited by 38
Labouesse, M. A., Gertz, E., Piccolo, B. D., de Souza, E. C. L., Schuster, G. U., Witbracht, M. G., Woodhouse, L. R., Adams, S. H., Keim, N. L., & Loan, M. D. V. (2014) · Bone · doi:10.1016/j.bone.2014.03.047 · Cited by 37
Incretins and bone: Evolving concepts in nutrient-dependent regulation of bone turnover
Yavropoulou, M. P., & Yovos, J. G. (2013) · HORMONES · doi:10.14310/horm.2002.1405 · Cited by 28
Hinton, P. S., Rector, R. S., Donnelly, J. E., SMITH, B. K., & Bailey, B. W. (2010) · European Journal of Clinical Nutrition · doi:10.1038/ejcn.2009.156 · Cited by 25
Glendenning, P. (2011) · Europe PMC (PubMed Central) · Cited by 20
Weight loss, weight regain and bone health
Pines, A. (2012) · Climacteric · doi:10.3109/13697137.2012.667975 · Cited by 16
Milligan, T. P., Park, H. R., Noonan, K., & Price, C. P. (1997) · Clinica Chimica Acta · doi:10.1016/s0009-8981(97)00052-1 · Cited by 13
Research works printed but not linked: 1
- Henriksen DB, Alexandersen P, Bjarnason NH, et al. Role of gas- trointestinal hormones in postprandial reduction of bone resorp- tion. J Bone Miner Res. 2003;18(12):2180 -2189.
Cited by
Sorted by citations
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
Self-citationIncretin hormones: Their role in health and disease
Nauck, M. A., & Meier, J. J. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13129 · Cited by 950
Hygum, K., Starup‐Linde, J., Harsløf, T., Vestergaard, P., & Langdahl, B. L. (2017) · European Journal of Endocrinology · doi:10.1530/eje-16-0652 · Cited by 334
Liraglutide in Type 2 Diabetes Mellitus: Clinical Pharmacokinetics and Pharmacodynamics
Jacobsen, L. V., Flint, A., Olsen, A. K., & Ingwersen, S. H. (2016) · Clinical Pharmacokinetics · doi:10.1007/s40262-015-0343-6 · Cited by 217
Type 2 Diabetes and Osteoporosis: A Guide to Optimal Management
Paschou, S. Α., Dede, A. D., Anagnostis, P. G., Vryonidou, A., Morganstein, D. L., & Goulis, D. G. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-00042 · Cited by 206
Metadata
- Authors
- Iepsen, E. W., Lundgren, J. R., Hartmann, B., Pedersen, O., Hansen, T., Jørgensen, N. R., Jensen, J.-E. B., Holst, J. J., Madsbad, S., & Torekov, S. S.
- Affiliations
- University of Copenhagen (DK)
- Corresponding author
- Iepsen, Eva W.
- Torekov, Signe S.
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2015-08
- Volume
- 100
- Issue
- 8
- Pages
- 2909-2917
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W1934495549
- Cited by
- 193
- References
- 54
- Citations by year
- 2026: 16 · 2025: 39 · 2024: 21 · 2023: 15 · 2022: 16 · 2021: 9 · 2020: 11 · 2019: 24 · 2018: 15 · 2017: 10 · 2016: 9 · 2015: 8
- FWCI
- 14.41
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Funders
- Danish Diabetes Academy
- Ministério da Ciência, Tecnologia e Inovação
- Novo Nordisk
- Copenhagen Graduate School for Nanoscience and Nanotechnology
- Faculty of Health and Medical Sciences, University of Western Australia
- Hvidovre Hospital
- Novo Nordisk Fonden (NNF14OC0009787)
- Det Sundhedsvidenskabelige Fakultet, Københavns Universitet
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- GLP-1 receptor agonists, liraglutide, bone loss, bone formation, weight loss, obesity, obese women, bone mineral content, bone turnover markers, P1NP, C-terminal telopeptide of type I collagen, hypocaloric diet, weight maintenance, glucagon-like peptide-1, osteoporosis prevention
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Liraglutide, Adolescent, Adult, Aged, Bone Resorption, Female, Humans, Middle Aged, Obesity, Osteogenesis, Weight Loss, Receptors, Glucagon, Caloric Restriction, Glucagon-Like Peptide 1, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
